<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426007</url>
  </required_header>
  <id_info>
    <org_study_id>TD-2104</org_study_id>
    <nct_id>NCT03426007</nct_id>
  </id_info>
  <brief_title>Controlled Ovarian Stimulation and Human Uterine Lavage</brief_title>
  <official_title>Controlled Ovarian Stimulation and Human Uterine Lavage: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Previvo Genetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Previvo Genetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study intended to demonstrate the Previvo Uterine Lavage System's&#xD;
      ability to recover embryos from the uterus following either natural cycle (NC)/intrauterine&#xD;
      insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination&#xD;
      (IUI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi- center, multiple-arm, feasibility study to evaluate the&#xD;
      safety and efficacy of the Previvo System in the recovery of embryos.&#xD;
&#xD;
      This study will recruit up to 500 healthy premenopausal volunteers. Subjects will undergo&#xD;
      either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian&#xD;
      hyperstimulation (COH)/intrauterine insemination (IUI) and have the lavage procedure&#xD;
      performed 4-6 days post IUI. It is anticipated that embryos recovered will be cryopreserved&#xD;
      for future use or donated for future use.&#xD;
&#xD;
      Subjects will be followed up with for up to 30 days after the lavage procedure. All data will&#xD;
      be collected on paper CRFs and analyzed by the Principal Investigator and Study Sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Event Collection</measure>
    <time_frame>30-Days</time_frame>
    <description>Assessment of pain during procedure, bleeding experienced during procedure, and infection symptoms experienced subsequent to procedure. Assessment of fluid recovery, fluid loss through cervix, fluid accumulation in the uterus and fluid loss through fallopian tubes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of Embryos</measure>
    <time_frame>1 Day</time_frame>
    <description>Demonstrate the Previvo Uterine Lavage System's ability to recover embryos from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Uterine Lavage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uterine lavage</intervention_name>
    <description>embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).</description>
    <arm_group_label>Uterine Lavage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Premenopausal female 18-40 years of age&#xD;
&#xD;
          2. Physically healthy and reasonably healthy family medical history&#xD;
&#xD;
          3. Having both ovaries with patent fallopian tubes, no known reproductive problems&#xD;
&#xD;
          4. BMI between 18-35 Kg/m2&#xD;
&#xD;
          5. Presence of a normal uterine cavity as assessed by sonohysterogram (SHG),&#xD;
             hysterosalpingogram (HSG), or ultrasound&#xD;
&#xD;
          6. Evidence of normal uterine anatomy that would not prevent the introduction of the&#xD;
             lavage catheter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of, or presence of hydrosalpinx&#xD;
&#xD;
          2. Addiction to alcohol and/or narcotics&#xD;
&#xD;
          3. Had radiotherapy or chemotherapy&#xD;
&#xD;
          4. Existence of an ovarian cyst at the beginning of cycle with suspicion of malignancy or&#xD;
             a large benign cyst&#xD;
&#xD;
          5. Contraindication for oral contraceptive pills or other study medication&#xD;
&#xD;
          6. Clinically significant abnormal basic metabolic panel lab results&#xD;
&#xD;
          7. Positive test or history of any of the following conditions:&#xD;
&#xD;
               1. Human immunodeficiency virus (HIV)&#xD;
&#xD;
               2. Hepatitis B infection&#xD;
&#xD;
               3. Hepatitis C infection&#xD;
&#xD;
               4. Syphilis (RPR)&#xD;
&#xD;
               5. Chlamydial pelvic infection&#xD;
&#xD;
               6. Gonorrheal pelvic infection.&#xD;
&#xD;
               7. Positive Pregnancy Test&#xD;
&#xD;
          8. Prior IUD for 60 days or less, or one currently in place&#xD;
&#xD;
          9. Allergic to study materials, supplies and medication&#xD;
&#xD;
         10. Any active, uncontrolled, clinically significant medical condition as determined by&#xD;
             the treating principal investigator&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gheda Sahyun, MA</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex Nidal</last_name>
    <phone>323-420-6343</phone>
    <email>anidal@previvogenetics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gheda Sahyun, MA</last_name>
    <phone>650-823-9093</phone>
    <email>gsahyun@previvo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Punta Mita Hospital</name>
      <address>
        <city>Punta de Mita</city>
        <state>Nayarit</state>
        <zip>63734</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Najmabadi, MD</last_name>
      <phone>310-466-5132</phone>
      <email>najmabadi@reproductibe.org</email>
    </contact>
    <investigator>
      <last_name>Sam Najmabadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine lavage</keyword>
  <keyword>intrauterine insemination</keyword>
  <keyword>embryo</keyword>
  <keyword>blastocyst</keyword>
  <keyword>in vivo</keyword>
  <keyword>superovulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

